Marc Atger

The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study

Hakim Mahammedi, E. Planchat, Mélanie Pouget et al. · Oncology · 2016 · 138 citations

Medicine, Oncology, Pharmacology +17

Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer

Judith Passildas, Jean‐Christophe Eymard, Mélanie Pouget et al. · Cancer Medicine · 2021 · 59 citations · Full text

Medicine, Oncology, Pharmacology +15

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial

Lorenzo Guglielmetti, Elisa Ardizzoni, Marc Atger et al. · Trials · 2021 · 32 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

Shrikant Patil, Meseret Tamirat, K S Khazhidinov et al. · Trials · 2023 · 13 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13